Whole genome sequencing enhances molecular diagnosis of primary ciliary dyskinesia
- PMID: 39115449
- PMCID: PMC11600997
- DOI: 10.1002/ppul.27200
Whole genome sequencing enhances molecular diagnosis of primary ciliary dyskinesia
Abstract
Background: Primary ciliary dyskinesia (PCD) is a genetic disorder affecting motile cilia. Most cases are inherited recessively, due to variants in >50 genes that result in abnormal or absent motile cilia. This leads to chronic upper and lower airway disease, subfertility, and laterality defects. Given overlapping clinical features and genetic heterogeneity, diagnosis can be difficult and often occurs late. Of those tested an estimated 30% of genetically screened PCD patients still lack a molecular diagnosis. A molecular diagnosis allows for appropriate clinical management including prediction of phenotypic features correlated to genotype. Here, we aimed to identify how readily a genetic diagnosis could be made using whole genome sequencing (WGS) to facilitate identification of pathogenic variants in known genes as well as novel PCD candidate genes.
Methods: WGS was used to screen for pathogenic variants in eight patients with PCD.
Results: 7/8 cases had homozygous or biallelic variants in DNAH5, DNAAF4 or DNAH11 classified as pathogenic or likely pathogenic. Three identified variants were deletions, ranging from 3 to 13 kb, for which WGS identified precise breakpoints, permitting confirmation by Sanger sequencing. WGS yielded identification of a de novo variant in a novel PCD gene TUBB4B.
Conclusion: Here, WGS uplifted genetic diagnosis of PCD by identifying structural variants and novel modes of inheritance in new candidate genes. WGS could be an important component of the PCD diagnostic toolkit, increasing molecular diagnostic yield from current (70%) levels, and enhancing our understanding of fundamental biology of motile cilia and variants in the noncoding genome.
Keywords: ciliopathies; molecular diagnosis; primary ciliary dyskinesia; rare respiratory disease; whole genome sequencing.
© 2024 The Author(s). Pediatric Pulmonology published by Wiley Periodicals LLC.
Conflict of interest statement
A. Meynert received core funding from the UKRI Medical Research Council. M. Halachev received core funding from the UKRI Medical Research Council. J. A. Marsh received funding from the UKRI Medical Research Council and Lister Institute. A. Shoemark received consulting fees from Spirovant, Translate Bio and ReCode Therapeutics, as well as payment for events from Ethris, Translate Bio and Insmed. She declares participation in the CARE‐UK Trial steering committee, as well as roles in the European Respiratory Society Clinical Research Collaborations (EMBARC, BEATPCD, AMR), where EMBARC3 is supported by project partners Armata, AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, Grifols, Insmed, Janssen, LifeArc, Novartis, and Zambon. The Scottish Genome Partnership received funding from the UKRI Medical Research Council and the Chief Scientist Office of the Scottish Government. Don Urquhart received funding from the NHS Research Scotland. He declares payment from Vertex Pharmaceuticals for events and participation in AbbVie Pharmaceutical's advisory board. He declares unpaid roles as the deputy chair of the European Cystic Fibrosis Society Exercise Working Group. S. Unger received funding from the NHS Research Scotland. T. J. Aitman acknowledges funding from the UKRI Medical Research Council and the the Chief Scientist Office of the Scottish Government, as co‐investigator for SGP. He declares support and consulting fees from BioCaptiva plc, for which he was former Director and now consultant, as well as shareholder with BioCaptiva plc. P. Mill received funding from the UKRI Medical Research Council and from the European Research Council. She declares payment for an event from Pfizer. She declares her unpaid roles as a member of the Ciliopathy Alliance Scientific Advisory Board, PCD Research Scientific Advisory Panel, the UK Cilia Network leadership team and University of Porto UMIB Scientific Advisory Panel. The remaining authors declare no conflict of interest.
Figures


References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources